In the same study, a Notch-receptor-targeted therapeutic antibody, brontictuzumab (OMP-52M51), showed significant and preferential antitumour efficacy in an ACC PDX model bearing a NOTCH1 activating mutation. Here, NOTCH1 is linked to adrenal cortex carcinoma.